Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization

Stopped early · Phase 2

Conditions studied: Antibody Mediated Rejection

In brief

The purpose of this trial was to determine the safety and efficacy of eculizumab in the prevention of antibody-mediated rejection (AMR) in sensitized recipients of a living donor kidney transplant requiring desensitization therapy.

Key facts

Study ID

NCT01399593

Run by

Alexion Pharmaceuticals, Inc.

People needed

102

Starts

2011-11-02

Expected to finish

2015-11-13

Last updated by the study team

2017-10-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female patients ≥18 years old
• Patients with Stage IV or Stage V chronic kidney disease who will receive a kidney transplant from a living donor to whom they are sensitized and require desensitization prior to transplantation

You may not qualify if…

• ABO incompatible with living donor
• Any medical condition that, in the opinion of the Investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confounds the assessment of the patient

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — La Jolla, California, United States
• Study site — Los Angeles, California, United States
• Study site — San Francisco, California, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Atlanta, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Baltimore, Maryland, United States
• Study site — Boston, Massachusetts, United States
• Study site — Rochester, Minnesota, United States
• Study site — St Louis, Missouri, United States
• Study site — Livingston, New Jersey, United States
• Study site — New York, New York, United States
• Study site — Chapel Hill, North Carolina, United States
• Study site — Cincinnati, Ohio, United States
• Study site — Oklahoma City, Oklahoma, United States
• Study site — Houston, Texas, United States
• Study site — North Terrace, South Australia, Australia
• Study site — Camperdown, Australia
• Study site — Clayton VIC, Australia
• Study site — Parkville VIC, Australia
• Study site — Paris, France
• Study site — Paris, France
• Study site — Toulouse, France
• Study site — Tours, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.